Antiarrhythmic Therapy Market Size, Share, and Growth Forecast 2026 - 2033

The global antiarrhythmic therapy market size is likely to be valued at US$5.2 billion in 2026 and is estimated to reach US$7.8 billion by 2033, growing at a CAGR of 6% during the forecast period from 2026 to 2033, driven by the rising burden of atrial fibrillation and growing support for early rhythm control. New approvals and pipeline activity are also widening treatment options.

Driver - Rising Atrial Fibrillation Burden to Push Long-term Treatment Needs

Atrial fibrillation (AF) is the main source of antiarrhythmic demand. It is common, chronic, and often recurrent. Patients may need drug therapy for years to maintain normal rhythm. The American Heart Association reports that AF affects more than 6 million Americans, and the number is projected to double by 2030. The Centers for Disease Control and Prevention (CDC) states that AF contributes to about 158,000 deaths each year in the U.S. Prevalence also rises with age, from 0.2% below age 55 to 10% at age 85 and older.

The burden is also growing in other regions. The European Society of Cardiology (ESC) projects that AF prevalence will double by 2050. It cites aging, comorbidities, better awareness, and new detection technologies. More detection means more diagnosed patients. Many of them will be offered rhythm control, which widens the treated population.

Guideline Support for Early Rhythm Control to Reinforce Drug Use

Guidelines now favor early rhythm management. The 2023 ACC/AHA/ACCP/HRS guideline favors early, aggressive rhythm control. It states that antiarrhythmic drugs are practical for long-term maintenance of sinus rhythm, including in patients who decline ablation or prefer drug therapy. This keeps drug treatment relevant even as ablation grows.

Drug choice is also well defined. Flecainide and propafenone are options for patients without prior myocardial infarction or significant structural heart disease. Dronedarone suits patients without recent decompensated heart failure or severe left ventricular dysfunction. Dofetilide and sotalol are effective but need QT interval monitoring. This clear patient matching supports steady prescribing across several drug classes.

Restraint - Proarrhythmia and Toxicity Risks May Limit Wide Drug Use

Safety is the main trade-off. Dofetilide and sotalol are linked with torsades de pointes, so they require QT monitoring. Sotalol is best avoided in heart failure with reduced ejection fraction. Amiodarone adds toxicity concerns. A 2026 randomized trial in EP Europace compared dronedarone with amiodarone after ablation in 280 patients. At least one side effect occurred in 64.0% of amiodarone patients versus 40.9% with dronedarone. QTc prolongation was 15.4% versus 5.8%, and hypothyroidism was 26.5% versus 8.8%.

Ablation adds competition. The 2024 ESC guideline asks clinicians to refer suitable patients for catheter or surgical ablation through shared decision-making. It also asks them to consider drug side effects fully. As ablation access improves, some patients may avoid long-term drugs. Monitoring needs can also add cost and complexity.

Opportunity - Self-administered PSVT Therapy to Shift Care Outside Emergency Settings

Paroxysmal supraventricular tachycardia (PSVT) episodes often need urgent care. In December 2025, the U.S. Food and Drug Administration (FDA) approved Milestone Pharmaceuticals' Cardamyst (etripamil). It is the first self-administered nasal spray for rapid conversion of acute PSVT to sinus rhythm in adults. In the Phase III trial, 64% of patients converted within 30 minutes versus 31% with placebo. Median conversion time was about 17 minutes versus 54 minutes.

Cardamyst launched in mid-February 2026. Milestone built a 60-person national sales force that targets cardiologists and electrophysiologists. Early uptake is modest, with about 600 prescriptions filled for 560 patients through April 2026. The company is also starting a Phase 3 program in AF with rapid ventricular rate. The European Medicines Agency has accepted its marketing application, with a decision expected in the first half of 2027. Coverage and prescriber education will shape growth.

Novel Atrial Agents to Address Safety Gaps in Current Drugs

Current drugs leave gaps in safety and tolerability. This is attracting new development. XYRA is testing budiodarone, a mixed ion channel blocker with esterase metabolism. The company says it has a much shorter half-life than amiodarone and shows no tissue accumulation in human or animal studies. These are company statements and need confirmation in later trials.

The Phase 2/3 HARBOR-AF study targets patients who failed rhythm control with drugs or ablation, or failed rate control. It uses a 28-day run-in and wearable or implanted monitors to track AF burden. If results are positive, it could offer an option for hard-to-treat patients. Success will depend on efficacy, safety, and regulatory outcomes.

Drug Class Insights

Class III potassium channel blockers are predicted to lead with a share of about 41.8% in 2026, as they remain central to long-term rhythm control. This class includes amiodarone, dronedarone, sotalol, and dofetilide. Each has a defined role in guideline-based care. Their importance also comes from use in both atrial and ventricular arrhythmias.

Class I sodium channel blockers are estimated to be the fastest-growing class over the forecast period, as guidelines favor early rhythm control. Flecainide and propafenone are options for patients without prior myocardial infarction or significant structural heart disease. Generic availability can support wider use in suitable patients. Careful patient selection remains essential.

Indication Insights

Atrial fibrillation is anticipated to dominate with a share of around 56.4% in 2026, as it is the most common sustained arrhythmia and often needs long-term management. Patients may receive rhythm control, rate control, or both. The CDC reported AF on 232,030 U.S. death certificates in 2021, which shows the scale of the condition. This creates repeat prescriptions and long treatment durations.

Supraventricular tachycardia is expected to be the fastest-growing indication over the forecast period, as new self-administered options are entering care. Cardamyst gives patients with PSVT a way to treat episodes outside the emergency room. The segment remains small but is gaining attention. Adoption depends on coverage, awareness, and prescriber confidence.

North America Antiarrhythmic Therapy Market Trends

North America is predicted to dominate in 2026 globally with a share of approximately 39.6%, supported by a substantial atrial fibrillation (AF) patient population, established electrophysiology services, widespread access to cardiologists, and the availability of both established medicines and newer rhythm-control technologies. The U.S. Centers for Disease Control and Prevention (CDC) projects that approximately 12.1 million people in the United States will have AF by 2050, highlighting the long-term need for treatments that control abnormal heart rhythms and reduce associated complications.

U.S. Antiarrhythmic Therapy Market Trends

A share of nearly 68.1% is expected to be held by the U.S. in 2026 in North America, backed by a large AF population, strong access to specialist cardiac care, established reimbursement systems, and the availability of multiple pharmacological and interventional treatment options.

CDC data indicate that AF was mentioned on 232,030 U.S. death certificates in 2021 and was identified as the underlying cause of death in 28,037 cases. The CDC also estimates that AF contributes to approximately 450,000 hospitalizations annually, demonstrating the considerable clinical and healthcare burden associated with the condition. Product access and reimbursement decisions are important commercial factors as newer therapies may offer advantages in convenience or administration but still face competition from established generic medicines.

Asia Pacific Antiarrhythmic Therapy Market Trends

Asia Pacific is anticipated to be the fastest-growing region globally in 2026 with a share of around 29.7%, shaped by population aging, increasing cardiovascular risk factors, improvements in electrocardiography and ambulatory rhythm monitoring, and wider access to specialist cardiac services.

A 2026 analysis published in JACC: Asia, using Global Burden of Disease data, estimated that approximately 25.7 million people across Asia were living with AF or atrial flutter in 2021. The study projected that this number could rise to approximately 58.5 million by 2040, with population growth and aging identified as major contributors. These findings indicate a growing need for medicines that control heart rate, restore normal rhythm, or prevent recurrent arrhythmias.

China Antiarrhythmic Therapy Market Trends

China will likely lead in Asia Pacific in 2026 with a share of about 38.5%, supported by a large population of older adults, a rising burden of cardiovascular risk factors, and continued development of hospital-based cardiology and electrophysiology services.

A nationwide community-based survey involving 47,841 adults aged 45 years and older, conducted between 2014 and 2016, estimated AF prevalence at 1.8%, equivalent to approximately 7.9 million people. Prevalence varied geographically from 0.9% to 2.4%, indicating that disease burden and diagnostic needs are not uniform across the country. The survey also identified substantial gaps in awareness and treatment, including low anticoagulation use among high-risk patients.

India Antiarrhythmic Therapy Market Trends

In 2026, India is projected to account for a share of just about 12.6% in Asia Pacific, due to a large population, increasing recognition of cardiovascular disease, expanding hospital infrastructure, and the availability of generic versions of established antiarrhythmic medicines. However, reliable estimates of AF prevalence remain limited, partly as screening is not consistently performed across community and primary-care settings. Earlier studies generally reported prevalence estimates of 0.1% to 0.5%, but a technology-assisted, community-based screening study in rural Gujarat found AF in 1.6% of participants aged over 45 years.

Europe Antiarrhythmic Therapy Market Trends

Europe will likely witness steady growth over the forecast period with a share of roughly 22.4% in 2026 globally, supported by established cardiology services, specialist prescribing, and guideline-driven management of cardiac arrhythmias.

The European Society of Cardiology (ESC) published its 2024 AF management guidelines on August 30, 2024, introducing the AF-CARE framework. This approach prioritizes management of comorbidities and risk factors, avoidance of stroke and thromboembolism, reduction of symptoms through rate or rhythm control, and individualized evaluation and reassessment. The guidelines also emphasize that treatment decisions should reflect patient characteristics, clinical risks, and preferences rather than relying on a uniform approach.

Germany Antiarrhythmic Therapy Market Trends

Germany is predicted to register a substantial share of approximately 27.8% in 2026 in Europe. The country's established hospital network, specialist cardiology services, and capacity to provide both pharmacological and interventional treatment support demand for arrhythmia management. According to the German Heart Report 2022, Germany recorded 447,485 inpatient admissions associated with cardiac arrhythmias in 2021, compared with 438,921 in 2020. The report also recorded 28,219 deaths attributed to cardiac arrhythmias in 2021, up from 27,369 a year earlier. These figures highlight the considerable clinical burden requiring diagnosis, treatment, and continued monitoring.

U.K. Antiarrhythmic Therapy Market Trends

In Europe, the U.K. is predicted to hold nearly 17.6% in 2026, supported by the country's established healthcare infrastructure, specialist arrhythmia services, and the need to manage AF among an aging population with multiple chronic conditions. A population-based study published in The Lancet Regional Health - Europe examined electronic health records from 3.4 million people in England between 1998 and 2017. It found that the annual number of newly diagnosed AF cases increased from 117,880 in 1998 to 202,333 in 2017, representing a 72% rise. The increase in absolute diagnoses was largely associated with population aging, while the age- and sex-standardized incidence rate rose by 30% over the same period.

The global antiarrhythmic therapy market is moderately fragmented, with a few multinational brand owners and many generic manufacturers. Sanofi's dronedarone and Pfizer's dofetilide remain important branded products. Generic amiodarone, flecainide, propafenone, and sotalol create wide price competition. Milestone Pharmaceuticals has entered the PSVT segment with Cardamyst, and XYRA is developing budiodarone.

Competition is shifting from drug availability toward safety, convenience, and patient selection. Guidelines now stress shared decision-making and side effect monitoring. Ablation also competes with long-term drug therapy. As a result, companies are focusing on better tolerability and self-administered options. Head-to-head safety data, such as the 2026 dronedarone versus amiodarone trial, will influence prescribing.

Key Industry Developments:

• In April 2026, Johnson & Johnson MedTech announced the European launch of VARIPULSE Pro following CE Mark approval. The updated pulsed field ablation platform incorporates a new pulse sequence designed to improve procedural efficiency and reduce the time required to deliver ablation while maintaining lesion effectiveness.
• In April 2026, researchers reported results from the AVANT GUARD trial in The New England Journal of Medicine, comparing pulsed field ablation (PFA) with antiarrhythmic drug therapy as initial treatment for previously untreated persistent atrial fibrillation. At 12 months, estimated treatment success was 56% among patients assigned to PFA, compared with 30% among those assigned to drug therapy.
• In October 2025, Novartis initiated a Phase 2 clinical trial of PKN605, an investigational oral therapy for patients with atrial fibrillation. The randomized, placebo-controlled study is designed to assess whether the treatment reduces atrial fibrillation burden, alongside evaluating safety, tolerability, and pharmacokinetics.